Methemoglobin: Physiology, Causes, Diagnosis, and Treatment

Methemoglobin is an abnormal form of hemoglobin that develops when the iron contained within hemoglobin is oxidized from the ferrous state to the ferric state. This change prevents the affected hemoglobin from binding oxygen normally and can impair tissue oxygen delivery even when arterial oxygen tension appears normal.

Methemoglobinemia becomes clinically important when methemoglobin levels rise above the normal range and reduce functional oxygen-carrying capacity.

Understanding its causes, physiologic effects, diagnosis, monitoring limitations, and treatment is important when evaluating unexplained cyanosis or abnormal oxygen saturation.

What Is Methemoglobin?

Methemoglobin, commonly abbreviated MetHb, is a dysfunctional form of hemoglobin in which the iron within the heme group has been oxidized.

Normal hemoglobin contains iron in the ferrous state, written as Fe²⁺. Ferrous iron is capable of binding oxygen reversibly, which allows hemoglobin to load oxygen in the lungs and release it to tissues. In methemoglobin, the iron loses an electron and becomes ferric iron, written as Fe³⁺. Ferric iron cannot bind oxygen normally.

The conversion can be summarized as:

Fe²⁺ → oxidation → Fe³⁺

Once hemoglobin becomes methemoglobin, that portion of the hemoglobin molecule no longer participates normally in oxygen transport.

A small amount of methemoglobin is normally present in the bloodstream because hemoglobin is continuously exposed to oxidizing substances. Under normal circumstances, enzyme systems within red blood cells reduce methemoglobin back to functional hemoglobin and keep the concentration low.

Normal adult methemoglobin levels are generally less than approximately 1% to 3% of total hemoglobin, depending on the laboratory reference range and measurement method.

What Is Methemoglobinemia?

Methemoglobinemia occurs when the amount of methemoglobin in the blood rises above the normal range.

The condition is important because increasing methemoglobin reduces the amount of hemoglobin capable of carrying oxygen. This creates a functional impairment in oxygen transport even when total hemoglobin concentration is adequate. Methemoglobinemia can be congenital or acquired.

Congenital forms are less common and may result from abnormalities involving enzymes responsible for reducing methemoglobin back to normal hemoglobin. Acquired methemoglobinemia is more common and usually develops after exposure to oxidizing medications or chemicals.

How Methemoglobin Affects Oxygen Transport

Methemoglobinemia impairs oxygen delivery through more than one mechanism.

Reduced Functional Hemoglobin

The first problem is straightforward. Hemoglobin molecules containing ferric iron cannot bind oxygen normally. As methemoglobin concentration rises, the amount of functional hemoglobin available for oxygen transport falls.

A patient may therefore have a normal total hemoglobin concentration but significantly less hemoglobin available to carry oxygen.

For example, if a patient has a total hemoglobin concentration of 14 g/dL but a substantial percentage exists as methemoglobin, the effective oxygen-carrying capacity is lower than the total hemoglobin value suggests. This distinction is important because total hemoglobin concentration does not indicate how much hemoglobin is actually functional.

Increased Oxygen Affinity of Remaining Hemoglobin

Methemoglobin also affects the oxygen-binding behavior of the remaining functional portions of the hemoglobin molecule. The presence of ferric iron increases oxygen affinity at the remaining normal binding sites.

This shifts the oxyhemoglobin dissociation curve to the left. A leftward shift means hemoglobin holds oxygen more tightly. Oxygen may load effectively in the lungs but may not unload as readily at the tissue level.

Therefore, methemoglobinemia can impair tissue oxygen delivery through two mechanisms:

• Reduced functional oxygen-binding capacity
• Reduced oxygen unloading from the remaining functional hemoglobin

Note: The combination can produce tissue hypoxia despite apparently adequate oxygen tension in arterial blood.

Methemoglobin and PaO₂

One of the most important concepts in methemoglobinemia is the difference between PaO₂ and hemoglobin oxygen transport. PaO₂ represents the partial pressure of oxygen dissolved in arterial plasma. It does not directly measure how much oxygen is bound to hemoglobin.

Because methemoglobinemia primarily affects hemoglobin rather than dissolved oxygen, a patient may have a normal or even elevated PaO₂ while experiencing significant impairment in oxygen delivery. This can be confusing when interpreting an arterial blood gas.

A patient with methemoglobinemia may receive supplemental oxygen and produce a very high PaO₂. However, increasing dissolved oxygen does not correct the underlying problem if a large portion of hemoglobin cannot carry oxygen. For this reason, a normal or high PaO₂ does not rule out methemoglobinemia.

The Saturation Gap

A clue to abnormal hemoglobin may appear when different oxygen measurements do not agree.

A patient may have:

• A low or unexpectedly fixed pulse oximetry value
• A normal or elevated PaO₂
• Clinical cyanosis
• Symptoms suggesting tissue hypoxia

This discrepancy is sometimes referred to as a saturation gap. The exact method used to define the gap may vary, but the basic concept is that oxygen saturation measurements appear inconsistent with the arterial oxygen tension.

When this occurs, abnormal hemoglobin species such as methemoglobin or carboxyhemoglobin should be considered.

Methemoglobin and Pulse Oximetry

Standard pulse oximetry has significant limitations in patients with methemoglobinemia. Conventional pulse oximeters use two wavelengths of light, typically near 660 nm and 940 nm, to estimate the relative amounts of oxyhemoglobin and reduced hemoglobin.

This method assumes that these are the primary hemoglobin species present. Methemoglobin interferes with this assumption.

Why SpO₂ May Approach 85%

Methemoglobin absorbs light at both wavelengths used by standard pulse oximeters. As the amount of methemoglobin rises, the absorption ratio tends to approach a value the device interprets as an oxygen saturation near 85%.

As a result, significant methemoglobinemia may cause the displayed SpO₂ to trend toward approximately 85%, regardless of the patient’s true arterial oxygen tension. This creates an unusual pattern.

Increasing the inspired oxygen concentration may substantially increase PaO₂ while the pulse oximeter remains near 85%. This pattern should increase suspicion for methemoglobinemia.

Why Conventional Pulse Oximetry Is Unreliable

Standard pulse oximeters cannot accurately distinguish among multiple abnormal hemoglobin species. They are primarily designed to differentiate oxyhemoglobin from reduced hemoglobin.

When methemoglobin is present in significant quantities, the displayed SpO₂ may not represent true functional arterial oxygen saturation. This is why pulse oximetry should not be used alone to confirm or exclude methemoglobinemia.

Clinical Appearance

Methemoglobinemia may produce several physical findings. One of the most recognizable is cyanosis.

The skin may appear:

• Blue-gray
• Slate-gray
• Dusky
• Cyanotic

The discoloration can persist despite oxygen administration. Blood may also appear unusually dark, chocolate-brown, or brown. Unlike ordinary deoxygenated blood, the color may not change significantly when the blood is exposed to oxygen.

These findings are not diagnostic by themselves, but they should raise suspicion when combined with an unexplained oxygen saturation abnormality.

Signs and Symptoms

Clinical manifestations depend partly on the percentage of hemoglobin converted to methemoglobin, the patient’s underlying health, hemoglobin concentration, and overall oxygen demand.

Patients with anemia, cardiac disease, pulmonary disease, or limited physiologic reserve may develop symptoms at lower methemoglobin concentrations.

Mild Elevations

Small increases may produce few or no symptoms. Possible findings include:

• Mild cyanosis
• Headache
• Fatigue
• Lightheadedness

Moderate Elevations

As levels increase, impaired oxygen delivery may become more apparent. Possible manifestations include:

• Dyspnea
• Tachypnea
• Tachycardia
• Weakness
• Dizziness
• Confusion
• Exercise intolerance

Severe Elevations

Marked methemoglobinemia may produce serious tissue hypoxia. Possible findings include:

• Altered mental status
• Severe respiratory distress
• Cardiac dysrhythmias
• Hypotension
• Seizures
• Coma
• Cardiovascular collapse

Note: Very high levels can be fatal. The percentage associated with specific symptoms varies among patients, so clinical status should always be considered alongside the measured methemoglobin concentration.

Causes of Methemoglobinemia

Methemoglobinemia can develop from inherited disorders or acquired exposure to oxidizing substances.

Congenital Methemoglobinemia

Congenital methemoglobinemia is uncommon. It may result from deficiency or dysfunction of enzyme systems responsible for reducing ferric iron back to the ferrous state.

Normally, red blood cells continuously convert small amounts of methemoglobin back into functional hemoglobin. When these reducing systems are impaired, methemoglobin may accumulate.

Certain abnormal hemoglobin variants may also predispose a patient to chronically elevated methemoglobin levels. Patients with congenital forms may have long-standing cyanosis despite relatively stable cardiopulmonary function.

Acquired Methemoglobinemia

Acquired methemoglobinemia is more common. It develops after exposure to medications, chemicals, or other oxidizing agents that overwhelm the red blood cell’s normal protective mechanisms. Several drugs have been associated with methemoglobin formation.

Examples include:

• Benzocaine
• Lidocaine
• Prilocaine
• Dapsone
• Inhaled nitric oxide
• Sodium nitroprusside
• Nitroglycerin
• Certain oxidizing chemicals

Note: Drug-induced methemoglobinemia is an important consideration because the condition may initially be mistaken for worsening pulmonary oxygenation.

Local Anesthetics

Local anesthetic agents are among the better-known causes of acquired methemoglobinemia. Benzocaine, lidocaine, and prilocaine have all been associated with the condition.

Benzocaine

Benzocaine has a particularly strong association with methemoglobinemia. It may be used as a topical anesthetic in the mouth or airway during certain procedures. Because of the risk of methemoglobinemia, benzocaine should be used cautiously and avoided when safer alternatives are appropriate.

Lidocaine

Lidocaine is widely used during airway procedures, including flexible bronchoscopy. It may be administered through:

• Nebulization
• Topical airway application
• Nasal administration
• Direct instillation through a bronchoscope

Lidocaine can contribute to methemoglobinemia, particularly at higher doses. For routine bronchoscopy, the total dose is often kept within approximately 5 to 7 mg/kg in adults, with lower doses considered in patients who may be more vulnerable to adverse effects.

Older adults and patients with liver or cardiac disease may require additional caution because metabolism and clearance can be impaired.

Methemoglobinemia During Bronchoscopy

Bronchoscopy is a clinical setting where methemoglobinemia may be overlooked. Local anesthetics are commonly used to suppress gagging and coughing.

A patient may initially tolerate the procedure but later develop:

• Cyanosis
• A pulse oximetry value near 85%
• Dyspnea
• Unexpectedly dark blood
• A PaO₂ that is much higher than expected based on the pulse oximeter

Note: This pattern is especially suspicious when topical benzocaine or significant quantities of lidocaine have been administered. If the oxygen saturation remains low despite supplemental oxygen but PaO₂ is normal or elevated, methemoglobinemia should be considered.

Inhaled Nitric Oxide and Methemoglobin

Inhaled nitric oxide is another important cause of methemoglobin formation. Nitric oxide is used as a selective pulmonary vasodilator in certain clinical situations.

It may be used in patients with severe pulmonary hypertension or increased pulmonary vascular resistance and is particularly relevant in neonatal and pediatric respiratory care.

Nitric oxide can improve pulmonary blood flow and reduce pulmonary artery pressure. However, nitric oxide can also oxidize hemoglobin and increase methemoglobin levels.

Monitoring During Nitric Oxide Therapy

Patients receiving inhaled nitric oxide should be monitored for methemoglobinemia.

Monitoring commonly includes:

• Delivered nitric oxide concentration
• Inspired oxygen concentration
• Nitrogen dioxide concentration
• Methemoglobin concentration
• Clinical oxygenation response

Methemoglobin is important because rising levels may reduce oxygen-carrying capacity even while nitric oxide improves pulmonary vascular function.

Thus, the treatment can improve oxygenation from a pulmonary standpoint while simultaneously creating a hematologic limitation to oxygen transport if excessive methemoglobin develops.

Nitrogen Dioxide Formation

Nitric oxide reacts with oxygen and can form nitrogen dioxide, or NO₂. Nitrogen dioxide is toxic to the lungs.

High concentrations may contribute to:

• Cellular injury
• Airway irritation
• Pulmonary edema
• Hemorrhage
• Lung injury

Note: Because both nitrogen dioxide exposure and methemoglobin formation are related to nitric oxide administration, specialized delivery systems are used to control and monitor therapy.

Sodium Nitroprusside

Sodium nitroprusside is a potent vasodilator used in selected critical care situations. It has a very short half-life and may be used to reduce systemic vascular resistance or control blood pressure.

Methemoglobinemia is one possible adverse effect. Prolonged or excessive exposure increases the risk of toxicity. Because nitroprusside has additional toxic metabolites, extended administration requires careful monitoring and should generally be limited when possible.

Nitroglycerin

Nitroglycerin is another medication capable of contributing to methemoglobin formation. The risk is generally associated with larger or prolonged exposures.

Although clinically significant methemoglobinemia is not common with routine doses, it should remain part of the differential diagnosis when unexplained cyanosis and an abnormal oxygen saturation occur in an exposed patient.

Dapsone

Dapsone is a recognized cause of acquired methemoglobinemia. Its metabolites have oxidizing properties that can increase methemoglobin formation. The condition may develop even at therapeutic doses in susceptible patients.

Because dapsone-induced methemoglobinemia can persist or recur, careful monitoring may be required depending on the severity of exposure and symptoms.

Co-Oximetry and Hemoximetry

The preferred method for measuring methemoglobin is co-oximetry, also called hemoximetry. A co-oximeter uses spectrophotometry to analyze light absorption at multiple wavelengths. Different hemoglobin species absorb light differently.

These characteristics allow the instrument to distinguish among:

• Oxyhemoglobin
• Reduced hemoglobin
• Carboxyhemoglobin
• Methemoglobin

Note: Some systems can identify additional hemoglobin species as well. The result provides a direct measurement of the proportion of total hemoglobin present as methemoglobin.

Why Co-Oximetry Is Important

A standard arterial blood gas provides measurements such as:

• pH
• PaCO₂
• PaO₂

Some blood gas machines also report a calculated oxygen saturation. However, calculated saturation assumes a normal relationship between PaO₂ and hemoglobin saturation. That assumption becomes unreliable when abnormal hemoglobin is present.

A patient with methemoglobinemia may therefore have:

• High PaO₂
• A misleading calculated saturation
• A pulse oximeter reading near 85%
• Reduced true functional oxygen saturation

Note: Direct co-oximetry is more useful because it identifies the abnormal hemoglobin species itself.

Pulse CO-Oximetry

Some newer noninvasive devices use multiple wavelengths of light rather than the two wavelengths used in conventional pulse oximetry. These devices may estimate additional hemoglobin species. The methemoglobin measurement may be reported as SpMet.

Pulse CO-oximetry may be useful for continuous monitoring in patients who are at risk for methemoglobinemia. However, direct blood analysis remains important when precise measurement or diagnostic confirmation is required.

Limitations of Co-Oximetry

Although co-oximetry is the preferred diagnostic method, measurement errors can still occur.

Potential sources of interference include:

• Very high methemoglobin concentrations
• Sulfhemoglobin
• Hyperlipidemia
• Intravenous dyes
• Air bubbles
• Blood clots
• Incomplete hemolysis
• Improper sample preparation

Note: Certain substances may absorb wavelengths used by the analyzer and affect calculated hemoglobin fractions. Results should therefore always be interpreted in combination with clinical findings.

Methemoglobin and Functional Hemoglobin

It is useful to distinguish total hemoglobin from functional hemoglobin. Total hemoglobin includes all hemoglobin species present in the blood.

This can include:

• Oxyhemoglobin
• Reduced hemoglobin
• Carboxyhemoglobin
• Methemoglobin

Methemoglobin and carboxyhemoglobin are considered dysfunctional because they do not participate normally in oxygen transport.

A patient may therefore have an apparently normal total hemoglobin concentration while having a reduced concentration of functional hemoglobin. This is one reason that oxygen content may be reduced even if the hemoglobin concentration reported on a complete blood count appears normal.

Oxygen Content and Methemoglobinemia

Most oxygen in the blood is transported bound to hemoglobin. Only a small amount is dissolved directly in plasma. This explains why a high PaO₂ cannot fully compensate for severe methemoglobinemia.

Increasing FiO₂ may raise the amount of oxygen dissolved in plasma, but dissolved oxygen normally contributes only a small fraction of total oxygen content. Therefore, treatment must address the abnormal hemoglobin itself rather than relying exclusively on supplemental oxygen.

Methemoglobin and Tissue Hypoxia

Tissue hypoxia occurs when oxygen delivery is inadequate to meet cellular demand. In methemoglobinemia, oxygen delivery may fall even if ventilation and pulmonary gas exchange are functioning normally. The problem occurs downstream from the lungs.

Oxygen may enter the alveoli, diffuse into the bloodstream, and produce a normal PaO₂, yet tissue delivery remains impaired because hemoglobin cannot carry or release oxygen normally. This makes methemoglobinemia primarily a disorder of oxygen transport rather than a disorder of ventilation.

Differential Diagnosis

Several conditions may produce cyanosis or abnormal oxygen saturation.

Possible causes include:

• Severe hypoxemia
• Ventilation-perfusion mismatch
• Right-to-left shunting
• Low cardiac output
• Carboxyhemoglobinemia
• Methemoglobinemia
• Sulfhemoglobinemia
• Pulse oximeter artifact

Note: The patient’s history is essential. Exposure to nitric oxide, local anesthetics, dapsone, nitroprusside, or other oxidizing substances can provide an important clue. An unexpectedly normal or elevated PaO₂ despite cyanosis further supports the possibility of a dyshemoglobinemia.

Initial Management

Management begins with recognition and removal of the cause when possible. The first steps generally include:

• Stop the offending medication or chemical exposure
• Administer supplemental oxygen
• Confirm the methemoglobin level with co-oximetry
• Assess symptoms and hemodynamic status
• Determine whether specific antidotal treatment is required

Note: Oxygen should be administered even though it does not directly convert methemoglobin back to normal hemoglobin. It can maximize oxygen loading of the remaining functional hemoglobin and increase the small amount of oxygen dissolved in plasma.

Mild Methemoglobinemia

Lower levels of methemoglobin may resolve after the oxidizing agent is discontinued. In otherwise stable patients, the body’s normal reducing systems may gradually restore hemoglobin to its functional state. Recovery may occur over several hours.

Observation and supplemental oxygen may be sufficient when the patient has minimal symptoms and the methemoglobin concentration is relatively low. Clinical condition is more important than any single numeric threshold.

Methylene Blue

Methylene blue is the primary treatment for clinically significant methemoglobinemia. It acts as a reducing agent and helps convert ferric iron back toward the ferrous state. Treatment is generally considered when methemoglobin levels are significantly elevated or when the patient has symptoms of impaired oxygen delivery.

A commonly referenced threshold is approximately 20% to 30%, although treatment may be indicated at lower levels in symptomatic patients or those with limited cardiopulmonary reserve.

Patients with anemia, cardiovascular disease, pulmonary disease, or neurologic symptoms may require treatment sooner than otherwise healthy patients.

Ascorbic Acid

Ascorbic acid can also act as a reducing agent. Its effect is generally slower than that of methylene blue. It may be considered in selected situations, including cases where methylene blue cannot be used. The role of ascorbic acid depends on the clinical context and severity of methemoglobinemia.

Monitoring Response to Treatment

After treatment, methemoglobin levels should be reassessed.

Clinical improvement may include:

• Improved skin color
• Reduced dyspnea
• Improved mental status
• Better agreement between oxygen measurements
• Decreasing methemoglobin concentration

Note: Some drug exposures may cause recurrent methemoglobinemia because the responsible substance or its metabolites remain in the body. Continued observation may therefore be necessary.

Prevention

Prevention focuses on minimizing unnecessary exposure to oxidizing substances and monitoring patients receiving medications known to increase methemoglobin.

Important precautions include:

• Avoid unnecessary benzocaine exposure
• Limit total local anesthetic dose
• Monitor methemoglobin during inhaled nitric oxide therapy
• Use specialized nitric oxide delivery systems
• Monitor nitrogen dioxide concentrations
• Review medications when unexplained cyanosis occurs
• Use caution with prolonged nitroprusside exposure
• Consider patient risk factors before administering oxidizing medications

Note: Early recognition is especially important because methemoglobinemia can resemble pulmonary hypoxemia.

Methemoglobin and DLCO

Methemoglobin can also influence measurement of the diffusing capacity of the lungs for carbon monoxide, or DLCO. DLCO testing depends partly on the ability of hemoglobin to bind carbon monoxide. Abnormal hemoglobin species may alter this process.

Methemoglobin can reduce the ability of circulating hemoglobin to bind carbon monoxide normally and may contribute to a reduced measured DLCO. Therefore, a low DLCO does not always reflect a problem with the alveolar-capillary membrane alone. Hemoglobin concentration and hemoglobin abnormalities must also be considered when interpreting diffusion measurements.

Important Clinical Pattern

One of the most useful patterns to remember is:

Cyanosis + SpO₂ near 85% + normal or high PaO₂ + oxidizing drug exposure = consider methemoglobinemia

This pattern does not confirm the diagnosis, but it should prompt measurement of methemoglobin with co-oximetry. The patient’s clinical condition should always be assessed at the same time.

Key Points to Remember

Methemoglobin differs from normal hemoglobin because its iron is oxidized from Fe²⁺ to Fe³⁺. Ferric iron cannot bind oxygen normally.

As methemoglobin increases:

• Functional oxygen-carrying capacity decreases
• Remaining hemoglobin holds oxygen more tightly
• The oxyhemoglobin dissociation curve shifts left
• Tissue oxygen delivery can decline
• PaO₂ may remain normal or elevated
• Conventional pulse oximetry may become unreliable

Common causes include:

• Benzocaine
• Lidocaine
• Prilocaine
• Dapsone
• Nitric oxide
• Sodium nitroprusside
• Nitroglycerin
• Other oxidizing chemicals

Note: Co-oximetry is the preferred method for confirming and quantifying methemoglobin. Treatment begins with removal of the offending agent and oxygen administration. Methylene blue is commonly used for significant or symptomatic methemoglobinemia.

Methemoglobin Practice Questions

1. What is methemoglobin?
Methemoglobin is an abnormal form of hemoglobin in which the iron within the heme molecule has been oxidized from the ferrous state (Fe²⁺) to the ferric state (Fe³⁺).

2. What happens to the iron in hemoglobin when methemoglobin forms?
The iron loses an electron and changes from the ferrous state (Fe²⁺) to the ferric state (Fe³⁺).

3. Why is methemoglobin unable to transport oxygen normally?
Ferric iron (Fe³⁺) cannot bind oxygen normally, making that portion of hemoglobin unavailable for effective oxygen transport.

4. What is methemoglobinemia?
Methemoglobinemia is a condition in which an abnormally increased amount of methemoglobin is present in the blood.

5. How does methemoglobinemia reduce the oxygen-carrying capacity of blood?
It converts functional hemoglobin into methemoglobin, leaving less hemoglobin available to bind and transport oxygen.

6. How does methemoglobin affect the oxygen affinity of the remaining functional hemoglobin?
It increases the oxygen affinity of the remaining functional hemoglobin, causing oxygen to be held more tightly.

7. In which direction does methemoglobinemia shift the oxyhemoglobin dissociation curve?
It shifts the oxyhemoglobin dissociation curve to the left.

8. Why can a leftward shift of the oxyhemoglobin dissociation curve be harmful in methemoglobinemia?
A leftward shift causes hemoglobin to hold onto oxygen more tightly, reducing the release of oxygen to the tissues.

9. Can a patient with significant methemoglobinemia have a normal or elevated PaO₂?
Yes. PaO₂ measures oxygen dissolved in plasma and does not indicate whether hemoglobin can carry oxygen normally.

10. Why does a normal PaO₂ not rule out methemoglobinemia?
Because PaO₂ reflects dissolved oxygen in plasma rather than the functional oxygen-carrying capacity of hemoglobin.

11. What pulse oximetry value is commonly associated with significant methemoglobinemia?
The SpO₂ often trends toward approximately 85%.

12. Why does conventional pulse oximetry become unreliable in methemoglobinemia?
Standard pulse oximeters use two wavelengths of light and cannot reliably distinguish methemoglobin from normal oxyhemoglobin and reduced hemoglobin.

13. What clinical finding should raise suspicion for methemoglobinemia when the PaO₂ is high?
Cyanosis or a low pulse oximetry reading despite a normal or elevated PaO₂ should raise suspicion.

14. What color may the blood appear in a patient with methemoglobinemia?
The blood may appear dark brown or chocolate-brown.

15. What skin discoloration may occur with methemoglobinemia?
The patient may develop a slate-gray, blue-gray, or cyanotic appearance.

16. What is the preferred laboratory method for directly measuring methemoglobin?
Co-oximetry, also called hemoximetry, is the preferred method.

17. How does co-oximetry distinguish different hemoglobin species?
It uses spectrophotometry to measure how different hemoglobin species absorb multiple wavelengths of light.

18. Which hemoglobin species can commonly be measured by co-oximetry?
Co-oximetry can measure oxyhemoglobin, reduced hemoglobin, carboxyhemoglobin, and methemoglobin.

19. Why may a calculated oxygen saturation from an arterial blood gas be misleading in methemoglobinemia?
Calculated saturation assumes normal hemoglobin function and a normal relationship between PaO₂ and hemoglobin saturation.

20. What type of pulse oximeter can estimate methemoglobin noninvasively?
A multiwavelength pulse CO-oximeter can estimate methemoglobin.

21. What abbreviation may be used for methemoglobin measured by pulse CO-oximetry?
It may be reported as SpMet.

22. Which inhaled pulmonary vasodilator can increase methemoglobin levels?
Inhaled nitric oxide can increase methemoglobin levels.

23. Why should methemoglobin be monitored during inhaled nitric oxide therapy?
Nitric oxide can oxidize hemoglobin and increase methemoglobin, reducing functional oxygen-carrying capacity.

24. Which local anesthetic is particularly associated with methemoglobinemia?
Benzocaine is particularly associated with methemoglobinemia.

25. Which other medications may contribute to acquired methemoglobinemia?
Lidocaine, prilocaine, dapsone, nitroglycerin, sodium nitroprusside, and inhaled nitric oxide are examples of medications that may cause methemoglobinemia.

26. What is the normal role of red blood cell reducing systems in relation to methemoglobin?
They continuously convert small amounts of methemoglobin back into functional hemoglobin and help keep methemoglobin levels low.

27. What are the two broad categories of methemoglobinemia?
Methemoglobinemia may be congenital or acquired.

28. Which form of methemoglobinemia is more commonly associated with medications and chemicals?
Acquired methemoglobinemia is more commonly associated with oxidizing medications and chemicals.

29. What type of substances commonly cause acquired methemoglobinemia?
Oxidizing agents that overwhelm the red blood cell’s normal reducing mechanisms commonly cause acquired methemoglobinemia.

30. Why may patients with anemia develop symptoms of methemoglobinemia at lower levels?
They already have reduced oxygen-carrying capacity, so further loss of functional hemoglobin may impair oxygen delivery sooner.

31. Why may patients with cardiac or pulmonary disease tolerate methemoglobinemia poorly?
They often have limited physiologic reserve and may be less able to compensate for reduced oxygen delivery.

32. What mild symptoms may occur with elevated methemoglobin levels?
Possible symptoms include headache, fatigue, lightheadedness, and mild cyanosis.

33. What cardiovascular response may occur as methemoglobinemia becomes more significant?
Tachycardia may occur as the body attempts to compensate for impaired oxygen delivery.

34. What respiratory symptoms may occur with moderate methemoglobinemia?
Dyspnea and tachypnea may occur as tissue oxygen delivery becomes impaired.

35. What neurologic finding may develop in more severe methemoglobinemia?
Confusion or altered mental status may develop because of inadequate oxygen delivery to the brain.

36. What serious neurologic complication can occur with severe methemoglobinemia?
Seizures may occur in severe cases.

37. What life-threatening cardiovascular consequence can occur with very high methemoglobin levels?
Cardiovascular collapse can occur when tissue hypoxia becomes severe.

38. Why can methemoglobinemia be mistaken for a pulmonary oxygenation problem?
It can cause cyanosis and low pulse oximetry readings even though pulmonary oxygen transfer and PaO₂ may be relatively preserved.

39. Why might increasing FiO₂ fail to correct the underlying problem in methemoglobinemia?
Supplemental oxygen cannot restore the oxygen-binding ability of hemoglobin that has been converted to methemoglobin.

40. What should be suspected when SpO₂ remains near 85% despite a markedly elevated PaO₂?
A dysfunctional hemoglobin such as methemoglobin should be suspected.

41. Why is medication history important when evaluating suspected methemoglobinemia?
Exposure to oxidizing drugs can provide an important clue to the cause of an unexplained abnormal oxygen saturation.

42. Why is bronchoscopy a setting in which methemoglobinemia may occur?
Topical and local anesthetics used during bronchoscopy, including benzocaine and lidocaine, can oxidize hemoglobin.

43. What should be considered if a patient becomes cyanotic after receiving topical airway anesthesia?
Acquired methemoglobinemia should be considered.

44. Why should the total dose of lidocaine be limited during bronchoscopy?
Excessive lidocaine exposure can increase the risk of adverse effects, including methemoglobinemia.

45. Which patients may require extra caution when receiving lidocaine?
Older adults and patients with hepatic or cardiac disease may require additional caution.

46. Why is benzocaine often avoided when possible?
It has a well-recognized association with acquired methemoglobinemia.

47. What toxic gas can form when inhaled nitric oxide reacts with oxygen?
Nitrogen dioxide, or NO₂, can form.

48. Why is nitrogen dioxide monitored during inhaled nitric oxide therapy?
Excessive nitrogen dioxide can cause cellular injury, pulmonary edema, hemorrhage, and other forms of lung toxicity.

49. What happens to functional hemoglobin as methemoglobin concentration rises?
The proportion of hemoglobin available for normal oxygen transport decreases.

50. Why is methemoglobinemia considered primarily a disorder of oxygen transport?
Oxygen may enter the lungs and dissolve in arterial blood normally, but abnormal hemoglobin limits the blood’s ability to carry and deliver that oxygen to tissues.

51. What is the first step in managing acquired methemoglobinemia?
The first step is to discontinue or remove the offending oxidizing medication or chemical whenever possible.

52. Why is supplemental oxygen administered to patients with methemoglobinemia?
Supplemental oxygen helps maximize oxygen loading of the remaining functional hemoglobin and increases the amount of oxygen dissolved in plasma.

53. Can supplemental oxygen alone correct significant methemoglobinemia?
No. Supplemental oxygen does not directly convert ferric iron back to the normal ferrous state.

54. What medication is commonly used to treat significant methemoglobinemia?
Intravenous methylene blue is commonly used to treat significant methemoglobinemia.

55. How does methylene blue help reverse methemoglobinemia?
It acts as a reducing agent that promotes conversion of ferric iron toward the functional ferrous state.

56. At approximately what methemoglobin level is active treatment commonly considered?
Active treatment is commonly considered when methemoglobin levels reach approximately 20% to 30%, especially when symptoms are present.

57. Why might treatment be necessary at a lower methemoglobin level in some patients?
Patients with anemia, cardiac disease, pulmonary disease, or significant symptoms may tolerate reduced oxygen delivery poorly and require earlier treatment.

58. What alternative reducing agent may be used in selected cases of methemoglobinemia?
Ascorbic acid may be used as a reducing agent in selected situations.

59. How does ascorbic acid compare with methylene blue in treating methemoglobinemia?
Ascorbic acid generally acts more slowly than methylene blue.

60. What may happen to mild methemoglobinemia after the offending agent is stopped?
It may resolve spontaneously as normal red blood cell reducing systems convert methemoglobin back toward functional hemoglobin.

61. Approximately how long may spontaneous recovery take in some mild cases?
Recovery may occur over approximately 15 to 20 hours.

62. Why should methemoglobin levels be rechecked after treatment?
Repeat measurement helps determine whether the abnormal hemoglobin concentration is decreasing and whether treatment has been effective.

63. Why can methemoglobinemia recur after initial improvement?
The responsible drug or its oxidizing metabolites may remain in the body and continue producing methemoglobin.

64. Why is total hemoglobin concentration alone insufficient for evaluating oxygen transport in methemoglobinemia?
Total hemoglobin includes both functional and dysfunctional hemoglobin, so it does not show how much hemoglobin is actually available to carry oxygen.

65. Which two abnormal hemoglobin forms commonly reduce the amount of functional hemoglobin?
Methemoglobin and carboxyhemoglobin both reduce the amount of functional hemoglobin available for normal oxygen transport.

66. What is oxyhemoglobin?
Oxyhemoglobin is hemoglobin that has oxygen bound to it.

67. What is reduced hemoglobin?
Reduced hemoglobin is hemoglobin that has released its oxygen and is not currently bound to oxygen.

68. How does methemoglobin differ from oxyhemoglobin?
Methemoglobin contains oxidized ferric iron and cannot bind oxygen normally, whereas oxyhemoglobin is functional hemoglobin carrying oxygen.

69. Why is direct hemoximetry more useful than PaO₂ alone when dyshemoglobinemia is suspected?
Hemoximetry identifies the proportions of different hemoglobin species, while PaO₂ only measures oxygen dissolved in plasma.

70. What technical problem can hyperlipidemia cause during co-oximetry?
Hyperlipidemia can scatter light and interfere with spectrophotometric measurements, potentially producing inaccurate hemoglobin values.

71. How can intravenous dyes interfere with co-oximetry?
Some dyes absorb wavelengths used by the analyzer and may distort measurements of hemoglobin species.

72. What sample problems can produce inaccurate co-oximetry results?
Air bubbles, blood clots, incomplete hemolysis, and improper sample preparation can interfere with accurate measurements.

73. At very high methemoglobin concentrations, what can happen to co-oximetry measurements?
Very high methemoglobin concentrations can interfere with the accurate measurement of different hemoglobin fractions.

74. How can methemoglobin affect the measured diffusing capacity for carbon monoxide?
Methemoglobin can reduce hemoglobin’s ability to bind carbon monoxide and may contribute to a lower measured DLCO.

75. Why should hemoglobin abnormalities be considered when interpreting a low DLCO?
A reduced DLCO may reflect abnormalities in hemoglobin or hemoglobin concentration rather than only impaired gas transfer across the alveolar-capillary membrane.

76. Why can cyanosis persist in methemoglobinemia even when supplemental oxygen is administered?
Because supplemental oxygen does not restore the oxygen-binding function of hemoglobin that has been converted to methemoglobin.

77. What does the term dysfunctional hemoglobin mean?
It refers to a form of hemoglobin that cannot participate normally in oxygen transport.

78. Why is methemoglobin considered a dyshemoglobin?
Because it is an abnormal hemoglobin species that cannot carry oxygen normally.

79. What is the normal oxidation state of iron in functional hemoglobin?
The iron is normally in the ferrous state, Fe²⁺.

80. What oxidation state is present in methemoglobin?
The iron is in the ferric state, Fe³⁺.

81. Why does methemoglobinemia impair tissue oxygen delivery even when the lungs are functioning normally?
Because the problem is with hemoglobin’s ability to carry and release oxygen rather than with oxygen entering the lungs.

82. What happens to oxygen unloading at the tissues when the oxyhemoglobin dissociation curve shifts left?
Oxygen unloading decreases because hemoglobin holds onto oxygen more tightly.

83. Why can methemoglobinemia produce cellular hypoxia without severe hypoxemia?
Because arterial oxygen tension may remain normal while hemoglobin-mediated oxygen transport is impaired.

84. What should be considered when a patient’s clinical appearance seems worse than the PaO₂ suggests?
An abnormal hemoglobin species such as methemoglobin should be considered.

85. Why is co-oximetry more informative than a conventional pulse oximeter in suspected methemoglobinemia?
Co-oximetry directly measures multiple hemoglobin species, while conventional pulse oximetry cannot reliably identify methemoglobin.

86. What is the main purpose of spectrophotometry in co-oximetry?
It distinguishes hemoglobin species based on their different light-absorption characteristics.

87. Why can conventional pulse oximetry give a misleading impression of oxygenation in methemoglobinemia?
The device assumes that oxyhemoglobin and reduced hemoglobin are the primary hemoglobin species present.

88. What should be done if pulse oximetry and the patient’s overall clinical status do not agree?
The clinician should evaluate for technical problems and consider direct measurement of abnormal hemoglobin species with co-oximetry.

89. Why should inspired nitric oxide concentration be carefully controlled?
Higher exposure increases the risk of complications such as methemoglobin formation and nitrogen dioxide production.

90. What is one reason specialized delivery systems are used for inhaled nitric oxide?
They help control the delivered nitric oxide concentration and allow monitoring of nitrogen dioxide and other safety parameters.

91. Why can nitric oxide therapy create a paradox in oxygen management?
It may improve pulmonary blood flow while also increasing methemoglobin, which can reduce the blood’s oxygen-carrying capacity.

92. What clinical problem may occur if sodium nitroprusside is used for a prolonged period?
Prolonged exposure can contribute to methemoglobinemia and other forms of toxicity.

93. Why should prolonged sodium nitroprusside administration generally be avoided when possible?
The risk of toxic effects, including methemoglobin formation, increases with extended exposure.

94. How can oxidizing medications overwhelm the body’s normal defenses against methemoglobin?
They can produce methemoglobin faster than red blood cell reducing systems can convert it back to functional hemoglobin.

95. Why may a patient with congenital methemoglobinemia have chronic cyanosis?
An inherited defect in methemoglobin-reducing pathways can allow persistently elevated methemoglobin levels.

96. What is the relationship between methemoglobin concentration and functional oxygen-carrying capacity?
As methemoglobin concentration increases, functional oxygen-carrying capacity decreases.

97. Why should methemoglobin be considered when evaluating unexplained cyanosis after medication administration?
Several commonly used medications can oxidize hemoglobin and produce acquired methemoglobinemia.

98. What combination of findings is strongly suggestive of methemoglobinemia?
Cyanosis, an SpO₂ near 85%, a normal or elevated PaO₂, and recent exposure to an oxidizing agent are strongly suggestive.

99. Why is clinical status important when deciding whether to treat methemoglobinemia?
Patients vary in how well they tolerate reduced oxygen delivery, so symptoms and underlying disease matter in addition to the measured methemoglobin level.

100. What is the central physiologic problem in methemoglobinemia?
The central problem is impaired oxygen transport caused by oxidation of hemoglobin iron, which reduces oxygen binding and limits oxygen release to tissues.

Final Thoughts

Methemoglobin is an abnormal form of hemoglobin that can significantly impair oxygen transport while producing oxygen measurements that may appear confusing or contradictory. The central abnormality is oxidation of hemoglobin iron from the ferrous to ferric state, which prevents normal oxygen binding and increases oxygen affinity at remaining functional sites.

A normal or elevated PaO₂ does not exclude methemoglobinemia, and conventional pulse oximetry may become unreliable.

Recognition depends on the clinical presentation, medication exposure, cyanosis, oxygen measurement discrepancies, and confirmation with co-oximetry. Prompt removal of the cause and appropriate treatment can restore effective oxygen transport.